Fmr LLC Arcus Biosciences, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Fmr LLC holds 4,180,791 shares of RCUS stock, worth $74.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,180,791

Previous 4,779,269 12.52%

Holding current value

$74.6 Million

Previous $90.2 Million 29.43%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$14.59 - $18.48 $8.73 Million - $11.1 Million	-598,478 Reduced 12.52%	4,180,791 $63.7 Million
Q1 2024 May 13, 2024	BUY	$14.83 - $20.18 $748,722 - $1.02 Million	50,487 Added 1.07%	4,779,269 $90.2 Million
Q4 2023 Feb 13, 2024	SELL	$13.43 - $19.63 $688,556 - $1.01 Million	-51,270 Reduced 1.07%	4,728,782 $90.3 Million
Q3 2023 Nov 13, 2023	BUY	$17.62 - $23.54 $3.92 Million - $5.23 Million	222,280 Added 4.88%	4,780,052 $85.8 Million
Q2 2023 Aug 11, 2023	BUY	$16.97 - $22.03 $21.2 Million - $27.5 Million	1,247,936 Added 37.7%	4,557,772 $92.6 Million
Q1 2023 May 11, 2023	SELL	$15.96 - $23.15 $95,376 - $138,344	-5,976 Reduced 0.18%	3,309,836 $60.4 Million
Q4 2022 Feb 13, 2023	SELL	$19.7 - $35.71 $776,889 - $1.41 Million	-39,436 Reduced 1.18%	3,315,812 $68.6 Million
Q3 2022 Nov 10, 2022	BUY	$23.23 - $30.07 $791,957 - $1.03 Million	34,092 Added 1.03%	3,355,248 $87.8 Million
Q2 2022 Aug 12, 2022	BUY	$17.23 - $37.73 $11,061 - $24,222	642 Added 0.02%	3,321,156 $84.2 Million
Q1 2022 May 13, 2022	BUY	$28.92 - $41.83 $3.68 Million - $5.32 Million	127,118 Added 3.98%	3,320,514 $105 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $3.21 Million - $4.96 Million	102,231 Added 3.31%	3,193,396 $129 Million
Q2 2021 Aug 13, 2021	BUY	$22.75 - $35.77 $70.3 Million - $111 Million	3,091,165 New	3,091,165 $84.9 Million

Others Institutions Holding RCUS

# of Institutions

203

Shares Held

48.9M

Call Options Held

173K

Put Options Held

151K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.29B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account